FundingWatcher
Home / Startups / Top biotech startups / Biotech startups in Asia

Biotech startups in Asia

Updated 16 Nov 2026

Reset
Biotech startups in Asia
One-time CSV
  • 2,567 funded companies, 1,519 with a website
  • Last round, amount, date, total raised and investors
  • CRM-ready CSV, 18 columns
  • Download right after payment
With founder contacts
Compiled to order
  • The full startup CSV, plus founders and executives
  • Up to 2 founders or CEOs per company, compiled to order
  • Name, job title and LinkedIn URL where found
  • Verified direct email per person
  • Startup CSV at once, contacts CSV by mail within 24 hours
Download right after paymentFree 10-row sampleSecure checkout by Stripe

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

startups-biotech~asia.csv2,567 rows × 18 columns
CompanyCityLast roundAmountDate
RemepyRamat GanSeries A$36.0M2026-08-12
altMBangaloreSeries A$10.3M2026-11-05
EnjosimShanghaiSeries B$30.1M2026-11-02
AusperBioHangzhouSeries C$120.0M2026-08-27
Drug FarmShanghaiSeries D$55.0M2026-07-13
Tianhu TechnologyMinhangSeries A$29.0M2026-07-13
Pandorum TechnologiesBangaloreSeries B$18.0M2026-02-09
HITSSeoulSeries B$13.5M2026-09-28

8 rows of the CSV in 5 of its 18 columns.

2,567
Startups
$37.8B
Total raised
385
Funded in the last 12 months
$6.0B
Raised in the last 12 months

Source: FundingWatcher. Data as of 16 November 2026. "Last 12 months" is the 365 days to that date.

Newest rounds

30 of 2,567
30 rows
Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
Huasaiboman Medical Cell Biology Huasaiboman Medical Cell Biology provides new cell therapy technologies and solutions as a biotechnology company. Biotech Qingdao Shi, China Series B $30.0M 2026-11-09 $30.0M ASBV 11 to 50 2019
Tushen Zhihe Tushen Zhihe provides artificial intelligence protein design services. Artificial intelligence Minhang, China Seed $1.4M 2026-11-09 $1.5M Wuxi Capital, CHENGMEI VENTURES 11 to 50 2023
altM altM is an alternate materials company. Biotech Bangalore, India Series A $10.3M 2026-11-05 $13.8M Omnivore, Theia Ventures, Thai Wah Ventures 11 to 50 2022
Enjosim Enjosim researches, manufactures, and sells self-delivery systems for biomacromolecule pharmaceuticals. Biotech Shanghai, China Series B $30.1M 2026-11-02 $30.1M Luminous Ventures (former Lightspeed China Partners), Jiayuan Capital 51 to 100 2021
Celaid Therapeutics Celaid Therapeutics develops cell therapies for blood cancer, intractable blood diseases, and genetic disorders. Biotech Tokyo, Japan Series B $2.5M 2026-10-05 $17.1M UTEC - The University of Tokyo Edge Capital Partners, Osaka University Venture Capital, Joyo Capital Partners 1 to 10 2020
M-Based M-Based develops eco-friendly alternative materials made from mycelium, the root structure of mushrooms. Biotech Ankara, Turkey Seed $700K 2026-10-01 $700K Hatcher+, Sente Ventures, Fark Labs 1 to 10
HITS HITS develops artificial intelligence software for drug discovery and pharmaceutical research. Artificial intelligence Seoul, South Korea Series B $13.5M 2026-09-28 $25.1M Korea Investment Partners, Capstone Partners, Company K Partners +2 11 to 50 2020
Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai, China Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
Apollon Apollon develops noninvasive continuous glucose monitoring systems. Artificial intelligence Seoul, South Korea Series A $3.7M 2026-09-22 $6.4M TIPS Program, KB Investment, TheVentures +2 11 to 50 2021
QL Biopharma QL Biopharma develops recombinant protein drugs to treat chronic metabolic diseases. Biotech Beijing, China Series C $44.7M 2026-09-14 $173.7M Chengdu Science and Technology Venture Capital, TF Capital, Lichen Capital +1 101 to 250 2018
Medefa Medefa uses synthetic biology to mass-produce novel PHA biomaterials. Biotech Zhuhai, China Series B $14.9M 2026-09-02 $16.3M Motianshi Touzi, Taiping Innovation 11 to 50 2019
Yuce Biotechnology Yuce Biotechnology focuses on the industrialization of single-molecule immunodiagnostic technologies. Biotech Suzhou, China Series B $7.4M 2026-08-31 $22.4M Puhua Capital, Zhengxuan Investment, BioTrack Capital +2 101 to 250 2019
AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
Hongxin Biology Hongxin Biology develops mRNA drugs and delivers nucleic acid therapeutics to patients. Biotech Shenzhen, China Series B $14.0M 2026-08-13 $14.0M Haiyuan Capital, Shenzhen Small & Medium Enterprises Credit Financing Guarantee Group 11 to 50 2021
Remepy Remepy develops hybrid drugs that combine multiple therapeutic approaches for biotechnology research. Artificial intelligence Ramat Gan, Israel Series A $36.0M 2026-08-12 $51.0M Samsung NEXT, NFX, Vine Ventures +2 11 to 50 2022
Phil Rivers Technology Phil Rivers Technology provides AI solutions for pharmaceutical research and development. Artificial intelligence Beijing, China Series A $29.6M 2026-08-05 $57.3M Insight Capital 51 to 100 2015
Layerwave Bio Layerwave Bio develops diagnostic instrument reagents and biomedical research instruments. Biotech Daxing, China Series B $13.8M 2026-07-28 $13.8M IDG Capital, Addor Capital, Hotung Venture Capital 51 to 100 2020
Diyingjia Technology Diyingjia Technology develops artificial intelligence software for medical imaging and treatment applications. Artificial intelligence Beijing, China Series C $3.0M 2026-07-28 $32.3M IDG Capital, Legend Capital, Microsoft Accelerator 11 to 50 2017
Shengqiang Technology Shengqiang Technology researches, manufactures, and sells high-tech products. Biotech Shenzhen, China Series C $13.7M 2026-07-26 $13.7M SDIC Venture Capital 101 to 250 2013
Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia, China Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
Drug Farm Drug Farm develops therapies for infectious, immunological, and inflammatory diseases using genetics and artificial intelligence. Artificial intelligence Shanghai, China Series D $55.0M 2026-07-13 $138.0M DT Capital Partners, South China Venture Capital, BVCF +1 101 to 250 2015
Tianhu Technology Tianhu Technology uses computational chemistry and artificial intelligence to design new drug molecules. Artificial intelligence Minhang, China Series A $29.0M 2026-07-13 $54.2M Qiming Venture Partners, GSR United Capital, 3E Bioventures 11 to 50 2021
MindRank AI MindRank AI develops artificial intelligence platforms to discover and develop small molecule drugs. Artificial intelligence Shanghai, China Series B $52.0M 2026-07-08 $101.0M Green Pine Capital Partners, Huagai Capital, Sherpa Healthcare Partners +1 11 to 50 2020
SynMetaBio SynMetaBio develops synthetic biological materials by combining synthetic biology with material design. Biotech Shanghai, China Series A $14.7M 2026-07-06 $16.1M MiraclePlus, Linear Capital, Danen Capital 11 to 50 2021
Prime Lifescience Prime Lifescience develops a big data platform for life sciences research and analysis. Biotech Hangzhou, China Series A $14.7M 2026-06-30 $44.5M Qiming Venture Partners, Qiji Investment, Ennovation Ventures 11 to 50 2021
Lingtai Krypton Biotechnology Lingtai Krypton Biotechnology develops lncRNA drugs to treat human diseases. Biotech Shuangliu, China Series A $13.7M 2026-06-26 $13.7M Legend Capital, Guosheng Capital, Firefly Haoyue 11 to 50 2021
Artivila Therapeutics Artivila Therapeutics uses artificial intelligence to discover new pharmaceutical drugs for patients. Artificial intelligence Shenzhen, China Series A $14.7M 2026-06-23 $53.3M Highlight Capital, Med-Fine Capital, Hike Capital +2 11 to 50 2018
MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian, China Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022
ThunderBio Innovation ThunderBio Innovation produces microfluidic chips, instruments, and reagents for laboratory applications. Biotech Jiaxing, China Series B $17.7M 2026-06-15 $34.6M Lucion, Guangzhou Financial Holding Fund Management, Zhuopu Touzi 11 to 50 2018
Dioseve Dioseve produces egg cells using DIOLs to create more reproductive possibilities. Biotech Tokyo, Japan Series A $6.2M 2026-06-11 $15.5M ANRI, Coral Capital, Archetype Ventures +2 11 to 50 2021

Table 1. Biotech startups in Asia: the 30 newest rounds whose row carries a description, a city, a named fund and an amount. Source: FundingWatcher. Data as of 16 November 2026. Base: 2,567.

Largest rounds

Last 12 months
10 rows
# Company What they do Sector Location Last round Amount Date Total raised Investors Employees Founded
1 CORXEL Pharmaceuticals CORXEL Pharmaceuticals develops medicines for underserved patients. Biotech Shanghai, China Series D $287.0M 2026-01-22 $451.8M Leaps by Bayer, RTW Investments 51 to 100 2019
2 New Radiomedicine Technology New Radiomedicine Technology supplies medical isotopes in China. Biotech Chengdu, China Series E $145.4M 2026-04-03 $330.6M Chengdu Science and Technology Venture Capital 101 to 250 2016
3 AusperBio AusperBio develops oligonucleotide therapeutics and targeted delivery technologies for treating diseases. Biotech Hangzhou, China Series C $120.0M 2026-08-27 $357.0M Qiming Venture Partners, BioVenture, Hankang Capital +1 51 to 100 2019
4 DP Technology DP Technology applies AI to scientific research and industrial R&D challenges worldwide. Artificial intelligence Haidian, China Series C $113.9M 2025-12-24 $253.7M Matrix Partners China, Qiming Venture Partners, Hillhouse Investment +1 101 to 250 2018
5 Full-Life Technologies Full-Life Technologies develops, produces, and commercializes medicines for cancer therapy. Biotech Shanghai, China Series D $109.0M 2026-05-18 $337.3M Sky9 Capital, Chengwei Capital, Prosperity7 Ventures +1 51 to 100 2021
6 D3 Bio D3 Bio develops and registers medicines as a biotechnology company. Biotech Wuxi Shi, China Series B $108.0M 2025-12-09 $370.0M Matrix Partners China, Boyu Capital, Medicxi 1 to 10 2020
7 Bluesail Surgical Bluesail Surgical develops surgical instruments for cardiovascular treatments. Biotech Shanghai, China Series B $104.5M 2026-09-23 $245.4M Huagai Capital, Linkong Private Equity Fund Management, Linqu County High-Tech Industrial Investment 101 to 250 2020
8 Delova Biotech Delova Biotech develops treatments for pain management. Biotech Qixia, China Series C $88.6M 2026-07-22 $109.8M Legend Capital, Peakview Capital, Hyfinity Investments +1 51 to 100 2017
9 Zenitar Zenitar conducts drug research and biomedical technology industrialization. Biotech Chengdu, China Series C $86.0M 2026-01-12 $155.7M Si Chuan Venture Capital, Chengdu High-tech Ceyuan Capital, New Value Capital 51 to 100 2019
10 MoleculeMind MoleculeMind combines artificial intelligence with biotechnology to develop new drugs and biological solutions. Artificial intelligence Haidian, China Series A $86.0M 2026-06-17 $114.6M Shenzhen Capital Group, Lenovo Capital and Incubator Group (LCIG), Sense Capital 51 to 100 2022

Table 2. Biotech startups in Asia: the 10 largest rounds of the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most active investors

By companies backed
#InvestorTypeLocation CompaniesShare Funded, 12 monthsLatest
1 Qiming Venture Partners Venture capital firm Shanghai, China 17 1% 7 AusperBio, Tianhu Technology, Prime Lifescience
2 TIPS Program Startup incubator Gangneung, South Korea 14 1% 1 Apollon
3 Legend Capital Venture capital firm Beijing, China 12 0% 5 Diyingjia Technology, Delova Biotech, Lingtai Krypton Biotechnology
4 Turkey Development Fund Fund of funds Umraniye, Turkey 12 0% 1 Viseur AI
5 Matrix Partners China Venture capital firm Beijing, China 11 0% 3 Alioth, DP Technology, D3 Bio
6 Kaitai Capital Venture capital firm Hangzhou, China 10 0% 2 Bivision, Levinthal
7 BioVenture Venture capital firm Suzhou, China 9 0% 4 AusperBio, Degron Therapeutics, Essentia Biosciences
8 Hillhouse Investment Angel group Singapore 9 0% 5 Etern, UniXell Biotechnology, Dishi Medical
9 CDH Investments Private equity firm Kowloon City, Hong Kong 8 0% 2 HemaCell, UniXell Biotechnology
10 Shenzhen Capital Group Venture capital firm Nanshan, China 7 0% 2 MoleculeMind, MAXVAX
11 Northern Light Venture Capital Venture capital firm Beijing, China 7 0% 1 HemaCell
12 IDG Capital Private equity firm Beijing, China 7 0% 3 Layerwave Bio, Diyingjia Technology, MAXVAX
13 Gaorong Capital Venture capital firm Wangjing, China 7 0% 3 BioGeometry, Bivision, Allink Biotherapeutics
14 CMB International Capital Corporation Investment bank Central, Hong Kong 6 0% 1 HemaCell
15 Lilly Asia Ventures Venture capital firm Shanghai, China 6 0%

Table 3. Biotech startups in Asia: the funds recorded as investors in the most companies. Latest: companies they back that raised in the last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Sectors

SectorsCompaniesShareTotal raised
Health care 2,017 79% $33.8B
Software 249 10% $3.7B
Artificial intelligence 172 7% $2.8B
Hardware 93 4% $241.3M
Energy 22 1% $886.3M
Cybersecurity 19 1%
Education 16 1% $21.8M
Commerce 15 1% $3.0M
Fintech 13 1%

Table 4. Biotech startups in Asia by sector. Source: FundingWatcher. Data as of 16 November 2026.

Funding stage

Funding stageCompaniesShareMedian last round
Pre-seed 123 5% $110K
Seed 933 36% $1.4M
Series A 721 28% $8.1M
Series B 457 18% $14.5M
Series C 235 9% $21.9M
Series D+ 98 4% $36.9M

Table 5. Biotech startups in Asia by stage of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Countries

CountriesCompaniesShare
China 1,440 56%
South Korea 340 13%
India 196 8%
Israel 189 7%
Japan 129 5%
Singapore 91 4%
Turkey 54 2%
Taiwan 44 2%
Hong Kong 24 1%
Indonesia 11 0%
Malaysia 8 0%
United Arab Emirates 8 0%

Table 6. Biotech startups in Asia by headquarters country. Source: FundingWatcher. Data as of 16 November 2026.

Cities

CitiesCompaniesShare
Shanghai 229 9%
Hangzhou 129 5%
Beijing 124 5%
Seoul 121 5%
Suzhou 109 4%
Shenzhen 98 4%
Singapore 86 3%
Nanjing 70 3%
Bangalore 55 2%
Guangzhou 52 2%
Haidian 49 2%
Tokyo 47 2%

Table 7. Biotech startups in Asia by headquarters city. Source: FundingWatcher. Data as of 16 November 2026.

Rounds by month

Rounds by monthCompaniesShareRaised
November 2026 13 3% $209.6M
October 2026 23 6% $197.5M
September 2026 32 8% $900.2M
August 2026 33 9% $549.8M
July 2026 42 11% $572.4M
June 2026 30 8% $399.6M
May 2026 33 9% $559.3M
April 2026 21 5% $395.9M
March 2026 31 8% $494.4M
February 2026 23 6% $281.3M
January 2026 43 11% $609.1M
December 2025 46 12% $735.0M
November 2025 15 4% $144.7M

Table 8. Biotech startups in Asia: most recent round by month, last 12 months. Source: FundingWatcher. Data as of 16 November 2026.

Most recent round by year

Most recent round by yearCompaniesShareRaised
2026 324 13% $5.2B
2025 316 12% $3.2B
2024 336 13% $1.9B
2023 330 13% $2.8B
2022 294 11% $5.3B
2021 274 11% $7.3B

Table 9. Biotech startups in Asia by year of the most recent round. Source: FundingWatcher. Data as of 16 November 2026.

Founding year

Founding yearCompaniesShare
2023 or later 216 9%
2020 to 2022 649 26%
2015 to 2019 1,004 40%
2010 to 2014 376 15%
Before 2010 270 11%

Table 10. Biotech startups in Asia by founding year. Source: FundingWatcher. Data as of 16 November 2026.

Team size

Team sizeCompaniesShare
1 to 10 507 24%
11 to 50 907 43%
51 to 100 335 16%
101 to 250 208 10%
251 to 500 73 3%
501 to 1,000 57 3%
1,001 to 5,000 28 1%
5,001 to 10,000 4 0%
10,001 or more 2 0%

Table 11. Biotech startups in Asia by headcount. Source: FundingWatcher. Data as of 16 November 2026.

Method

Sources, fields and exclusions of both files: Method.

Questions

How many biotech startups in Asia are on the list?
2,567, in the file dated 16 November 2026. 385 of them closed their most recent round in the last 12 months.
What does the CSV contain?
One row per company, 18 columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.
How much does the list cost?
$29 one-time for all 2,567 rows, no account. Every investor and every startup, two files, cost $99. With founder contacts, up to 2 founders or CEOs per company compiled to order and mailed within 24 hours, $349.
What arrives after payment?
At once: the CSV download link, on the page after payment and by mail.
Can I see rows before buying?
The 3 rows under the buy button are rows of the CSV with every column. The form below it mails 10 rows.
How current is the data?
The file is dated 16 November 2026. The download link serves the current file each time it is opened.

Biotech startups in Asia: 2,567 rows, CSV, $29 one-time.

At once: the CSV download link, on the page after payment and by mail.

Columns: name, domain, website, linkedin, description, founded, employees, city, region, country, sectors, funding_stage, last_round, last_round_date, last_round_usd, total_raised_usd, rounds, investors.

With founder contacts: $349 one-time. List CSV right after payment; up to 2 verified founder or CEO emails per company compiled to order within 24 hours.

Not sure about the data?

Download a free 10-row sample first. No account, no payment.

Biotech startups in Asia by funding stage

Other sectors in Asia

Biotech startups elsewhere

Cite: FundingWatcher, 2,567 funded biotech companies in Asia, 16 November 2026. https://fundingwatcher.com/startups/biotech/asia/